Preference for Fluzone vaccine [influenza virus vaccine] Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age.

Trial Profile

Preference for Fluzone vaccine [influenza virus vaccine] Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2014

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Jan 2010 Actual number of patients (110) added as reported by ClinicalTrials.gov record.
    • 13 Jan 2010 Actual end date (1 Jun 2008) added as reported by ClinicalTrials.gov record.
    • 13 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top